维布妥昔单抗用于儿童复发/难治性霍奇金淋巴瘤自体移植后的巩固治疗
本研究回顾性分析67例接受自体干细胞移植(ASCT)后以维布妥昔单抗巩固治疗的儿童复发/难治性霍奇金淋巴瘤(HL)患者,为目前最大样本队列。中位随访37个月,3年无进展生存(PFS)率为85%,安全性与成人患者相似。数据提示维布妥昔单抗在儿童复发/难治性HL自体移植后巩固治疗中可能发挥作用。
要点
- 儿童复发/难治性HL预后差,约50%患者会发生后续复发。
- 维布妥昔单抗巩固治疗耐受性良好,安全性特征与成人患者相似。
- 中位随访37个月,3年PFS率为85%。
核心结论
- 维布妥昔单抗用于儿童复发/难治性HL自体移植后巩固治疗耐受性良好,3年PFS率达85%,提示其可能的作用。
研究设计与样本
- 回顾性分析67例接受自体干细胞移植(ASCT)后以维布妥昔单抗巩固治疗的儿童复发/难治性霍奇金淋巴瘤(HL)患者,为迄今最大样本队列。
主要发现
- 维布妥昔单抗耐受性良好,安全性特征与成人患者相似。
- 中位随访37个月,3年无进展生存(PFS)率为85%。
临床怎么用
- 原文未据此给出推荐,数据提示维布妥昔单抗在儿童复发/难治性HL自体移植后巩固治疗中可能发挥作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody-drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/refractory HL.
引用
- Forlenza CJ, Rosenzweig J, Mauguen A, et al. Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Adv. 2023. PMID: 36897253. doi:10.1182/bloodadvances.2022009323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。